Clostridioides difficile infections, recurrences, and clinical outcomes in real-world settings from 2015 to 2019: The RECUR England study

被引:3
|
作者
Ghosh, Subrata [1 ,2 ]
Antunes, Ana [3 ,9 ]
Rinta-Kokko, Hanna [4 ]
Chaparova, Elena [5 ]
Lay-Flurrie, Sarah [6 ]
Tricotel, Aurore [7 ]
Andersson, Fredrik L. [8 ]
机构
[1] Univ Coll Cork, Coll Med & Hlth, Cork, Ireland
[2] Univ Birmingham, Birmingham, England
[3] IQVIA, Real World Solut, Global Database Studies, Lisbon, Portugal
[4] IQVIA, Real World Solut, Global Database Studies, Espoo, Finland
[5] IQVIA, Real World Solut, Sofia, Bulgaria
[6] IQVIA, Real World Solut, London, England
[7] IQVIA, Real World Solut, Paris, France
[8] Ferring Pharmaceut, Copenhagen, Denmark
[9] IQVIA, Lagoas Pk,Edificio 3, P-2740266 Lisbon, Portugal
关键词
Clostridioides difficile infection; Recurrent clostridioides difficile infection; Epidemiological; Real-world study; England; RECUR; RISK; DISEASE;
D O I
10.1016/j.ijid.2024.01.002
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: To estimate the epidemiological and clinical burden of Clostridioides difficile infections (CDIs) and recurrences (rCDIs) in England. Methods: This retrospective study included adult patients diagnosed with CDI (community or hospital settings) over 2015-2019 from Clinical Practice Research Datalink and Hospital Episode Statistics databases. Incidences of CDI and rCDI were determined annually. Time to subsequent rCDI was estimated by Kaplan-Meier method. Rates of complications were assessed within 12 months from index episode. Association of risk factors with complications was evaluated using a Cox regression model. Results: A total of 52,443 CDI episodes were recorded among 36,913 patients. Of these, 75% were aged >= 65 years, 59% were women; 73% were treated in community settings. CDI incidence remained stable (111 episodes per 10 0,0 0 0 patients in 2019). Around 21% of patients had >= 1 rCDI. Sepsis (12%) was the most common complication, followed by colectomy and ulcerative colitis. Age, gender, comorbidities, rCDI, preindex medical procedures, hospitalizations and consultations, and CDI treatment in hospital, were found to increase the risk of complication. Conclusions: CDI remains a concern in England. The study highlights the importance of managing primary and rCDI episodes via effective and improved therapies to prevent fatal complications. (c) 2024 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码:31 / 38
页数:8
相关论文
共 50 条
  • [1] Epidemiological and clinical burden of Clostridioides difficile infections and recurrences between 2015 − 2019: the RECUR Germany study
    Aurore Tricotel
    Ana Antunes
    Adrian Wilk
    Silvia Dombrowski
    Hanna Rinta-Kokko
    Fredrik L. Andersson
    Subrata Ghosh
    BMC Infectious Diseases, 24
  • [2] Epidemiological and clinical burden of Clostridioides difficile infections and recurrences between 2015-2019: the RECUR Germany study
    Tricotel, Aurore
    Antunes, Ana
    Wilk, Adrian
    Dombrowski, Silvia
    Rinta-Kokko, Hanna
    Andersson, Fredrik L.
    Ghosh, Subrata
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [3] Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: The RECUR England study
    Ghosh, Subrata
    Antunes, Ana
    Rinta-Kokko, Hanna
    Chaparova, Elena
    Lay-Flurrie, Sarah
    Tricotel, Aurore
    Andersson, Fredrik L.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2024, 142
  • [4] Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: the RECUR Germany study
    Antunes, Ana
    Tricotel, Aurore
    Wilk, Adrian
    Dombrowski, Silvia
    Rinta-Kokko, Hanna
    Andersson, Fredrik L.
    Ghosh, Subrata
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [5] A Real-World Study on the Clinical Characteristics, Outcomes, and Relationship between Antibiotic Exposure and Clostridioides difficile Infection
    Vintila, Bogdan Ioan
    Arseniu, Anca Maria
    Morgovan, Claudiu
    Butuca, Anca
    Birlutiu, Victoria
    Dobrea, Carmen Maximiliana
    Rus, Luca Liviu
    Ghibu, Steliana
    Bereanu, Alina Simona
    Arseniu, Rares
    Roxana Codru, Ioana
    Sava, Mihai
    Gabriela Gligor, Felicia
    ANTIBIOTICS-BASEL, 2024, 13 (02):
  • [6] A systematic review of real-world healthcare resource use and costs of Clostridioides difficile infections
    Malone, Daniel C.
    Armstrong, Edward P.
    Gratie, Dan
    Pham, Sissi V.
    Amin, Alpesh
    ANTIMICROBIAL STEWARDSHIP & HEALTHCARE EPIDEMIOLOGY, 2023, 3 (01):
  • [7] Clinical Burden of Recurrent Clostridioides difficile Infection: A Real-World Data Analysis
    Stong, Laura
    Nelson, Winnie W.
    Feuerstadt, Paul
    Boules, Mena
    Sacks, Naomi
    Portelli, Alexandria
    Healey, Bridget
    Lang, Kathleen
    Dahdal, David N.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S95 - S96
  • [8] REAL-WORLD OUTCOMES ASSOCIATED WITH BEZLOTOXUMAB USE AMONG MEDICARE BENEFICIARIES WITH CLOSTRIDIOIDES DIFFICILE INFECTION
    Dubberke, E.
    Puckett, J.
    Obi, E. N.
    Kamal-Bahl, S.
    Desai, K.
    Stuart, B.
    Doshi, J.
    VALUE IN HEALTH, 2022, 25 (07) : S330 - S330
  • [9] Washed microbiota transplantation for Clostridioides difficile infection: A national multicenter real-world study
    Wu, Xia
    Ai, Ru Jun
    Xu, Jie
    Wen, Quan
    Pan, Hua Qin
    Zhang, Zhi Hua
    Ning, Wang
    Fang, Ying
    Ding, Da Fa
    Wang, Quan
    Han, Shuang
    Liu, Xiao
    Wu, Mei
    Jia, Zhen Yu
    Jia, Song
    Lin, Tao
    Cui, Bo Ta
    Nie, Yong Zhan
    Wang, Xin
    Zhang, Fa Ming
    JOURNAL OF DIGESTIVE DISEASES, 2023, 24 (10) : 540 - 549
  • [10] Clinical complications in patients with primary and recurrent Clostridioides difficile infection: A real-world data analysis
    Feuerstadt, Paul
    Boules, Mena
    Stong, Laura
    Dahdal, David N.
    Sacks, Naomi C.
    Lang, Kathleen
    Nelson, Winnie W.
    SAGE OPEN MEDICINE, 2021, 9